111.43

1.85% 2.02

After Hours: 111.01 -0.42 -0.38%

Jazz Pharmaceuticals Plc (JAZZ)

Overview News Price History Option Chain Financials Discussions Forecast

Jazz Pharmaceuticals Plc stock is traded at $111.43, with a volume of 620.24K. It is up +1.85% in the last 24 hours and up +1.87% over the past month. Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Previous Close:

$109.41

Open:

$108.87

24h Volume:

620.24K

Relative Volume:

1.00

Market Cap:

$6.80B

Revenue:

$3.84B

Net Income/Loss:

$330.79M

P/E Ratio:

-70.97

EPS:

-1.57

Net Cash Flow:

$983.48M

1W Performance:

-0.43%

1M Performance:

+1.87%

6M Performance:

+1.29%

1Y Performance:

-15.62%

1-Day Range:

$108.73

$111.71

1-Week Range:

$108.73

$113.58

52-Week Range:

$99.06

$134.48

Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile

Name

Jazz Pharmaceuticals Plc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

353-1-634-7800

Address

FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN

Employee

2,800

Twitter

@jazzpharma

Next Earnings Date

2024-11-06

Latest SEC Filings

JAZZ's Discussions on Twitter

Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-03-24	Initiated	Robert W. Baird	Outperform
Nov-27-23	Downgrade	UBS	Buy → Neutral
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight
Dec-09-22	Upgrade	Goldman	Neutral → Buy
Jun-14-22	Initiated	UBS	Buy
Apr-06-22	Downgrade	Goldman	Buy → Neutral
Nov-19-21	Resumed	Goldman	Buy
Oct-07-21	Resumed	Jefferies	Buy
Oct-05-21	Initiated	Citigroup	Buy
Sep-23-21	Initiated	Needham	Buy
May-19-21	Resumed	JP Morgan	Overweight
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-05-21	Reiterated	H.C. Wainwright	Buy
Feb-03-21	Upgrade	Piper Sandler	Neutral → Overweight
Jan-29-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-16-20	Initiated	UBS	Buy
Nov-03-20	Reiterated	H.C. Wainwright	Buy
Oct-09-20	Reiterated	H.C. Wainwright	Buy
Sep-14-20	Downgrade	Goldman	Neutral → Sell
Sep-14-20	Resumed	JP Morgan	Overweight
Aug-06-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-28-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jul-23-20	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-06-20	Initiated	Jefferies	Buy
Mar-12-20	Upgrade	Bernstein	Mkt Perform → Outperform
Jan-08-20	Initiated	Goldman	Neutral
Aug-21-19	Downgrade	Piper Jaffray	Overweight → Neutral
Jun-11-19	Initiated	Barclays	Overweight
Mar-20-19	Initiated	SunTrust	Buy
Dec-14-18	Initiated	Wolfe Research	Peer Perform
Nov-08-18	Reiterated	B. Riley FBR	Buy
Aug-08-18	Reiterated	Stifel	Buy
Jul-11-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-23-18	Reiterated	H.C. Wainwright	Neutral
Mar-19-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight

View All

Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News

12:23 PM

Jazz Pharmaceuticals Iberia Recognized as One of the 100 Best Companies To Work for in Spain - CSRwire.com

12:23 PM

Nov 04, 2024

Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key Metrics - Yahoo Finance

Nov 04, 2024

Nov 03, 2024

Private Advisor Group LLC Acquires 5,437 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Nov 03, 2024

Nov 01, 2024

9 Best Biotech Stocks Of November 2024 - Forbes

Nov 01, 2024

Court Denies Jazz’s Challenge of Avadel’s Orphan Drug Lumryz - Sleep Review

Nov 01, 2024

US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle - Yahoo Finance

Nov 01, 2024

International Assets Investment Management LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Nov 01, 2024

Oct 31, 2024

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia - StockTitan

Oct 31, 2024

Court upholds FDA approval of Avadel's narcolepsy drug LUMRYZ - Investing.com

Oct 31, 2024

Avadel Pharma Shares Rise on Favorable Ruling for FDA in Lumryz Litigation - Marketscreener.com

Oct 31, 2024

Jazz Pharma Loses Lawsuit Over FDA Approval of Rival Sleep Drug - Bloomberg Law

Oct 31, 2024

Court upholds FDA approval of Avadel's narcolepsy drug LUMRYZ By Investing.com - Investing.com UK

Oct 31, 2024

Avadel soars after court rules in favor of FDA in Lumryz case with Jazz Pharma - MSN

Oct 31, 2024

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation - The Manila Times

Oct 31, 2024

State of Alaska Department of Revenue Buys 26,370 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Oct 31, 2024

Oct 30, 2024

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Oct 30, 2024

Jazz Pharmaceuticals (JAZZ) Set to Announce Earnings on Wednesday - MarketBeat

Oct 30, 2024

China Universal Asset Management Co. Ltd. Buys 4,472 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Oct 30, 2024

Drug Resistant Epilepsy Market Size, Industry Analysis, - openPR

Oct 30, 2024

Oct 29, 2024

With A 10% Return On Equity, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A Quality Stock? - Yahoo Finance

Oct 29, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.

Oct 29, 2024

Oct 27, 2024